ScreenerHero

PGENPrecigen Inc

NAS · US · Healthcare · Biotechnology · precigen.com
7.200USD+0.56%Mkt Cap: 2.57B $P/E: —

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious di…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap2.57B $
Enterprise Value2.72B $
Revenue (TTM)85.72M $
Gross Profit4.86M $
Net Income (TTM)-250.64M $
Revenue/Share0.2500 USD
Last Price7.200 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees160
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS74017N1054
Valuation
P/E (Trailing)—
P/E (Forward)-33.82
PEG—
EV/EBITDA-77.04
EV/Revenue31.78
P/S31.08
P/B60.98
EPS (TTM)-1.11
EPS (Forward)-0.22
52W Range
2.62094% of range7.500
52W High7.500 USD
52W Low2.620 USD
Profitability
Gross Margin50.20%
Oper. Margin41.18%
EBITDA Margin-41.25%
Profit Margin-2588.21%
ROE-1198.61%
ROA-161.18%
Growth
Revenue Growth6322.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-87.83M $
CapEx (TTM)2.00M $
FCF Margin-116.78%
FCF Yield-3.90%
Net Debt60.14M $
Net Debt/EBITDA-1.70
Balance Sheet
Debt/Equity4.70
Current Ratio4.58
Quick Ratio3.76
Book Value/Sh0.1220 USD
Cash/Share0.1070 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.50 USD
Upside (mean)+101.4%
Target Range11.00 USD – 18.00 USD
$11.00+101.4% to mean$18.00
# Analysts2
Ownership
Shares Out.356.51M
Float194.50M
Insiders12.67%
Institutions72.44%
Short Interest
Short Ratio10.4d
Short % Float21.54%
Short % Out.11.74%
Shares Short42.04M
Short (prev mo.)44.22M
Technical
SMA 505.713 (+26.0%)
SMA 2004.480 (+60.7%)
Beta1.01
S&P 52W Chg18.16%
Avg Vol (30d)4.97M
Avg Vol (10d)5.99M
Technical Indicators
RSI (14)65.5
MACD0.4096
MACD Signal0.4031
MACD Hist.+0.0065
BB Upper7.690 USD
BB Middle6.396 USD
BB Lower5.103 USD
BB Width40.45%
ATR (14)0.4241 USD
Vol Ratio (20d)0.75x